$15M Investment Helps Secure Funding for Phase 2 Trial of T3D-959 for Alzheimer’s
T3D Therapeutics has secured the needed funding to move forward with its Phase 2 trial testing T3D-959 as a potential treatment for people with mild-to-moderate Alzheimer’s disease. The total funding includes $15 million from an investor, in addition to a $9 million award from the…